MOBI · Mobia Medical, Inc. · Investor Relations
The latest filing states the doubt was alleviated.
“In prior reporting periods, the Company concluded that recurring operating losses, negative cash flows from operations, and future expenditures raised substantial doubt about its ability to continue as a going concern. In May 2026, the Company completed its IPO and received net proceeds of approximately $134.0 million. As a result of the additional liquidity provided by the completed IPO, management concluded that the existing cash and cash equivalents are sufficient to fund its operations and meet its obligations for at least one year from the date these condensed unaudited interim financial statements are issued. Accordingly, management concluded that the conditions and events described above do not raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-11-05 21:30 UTC | Third Quarter 2026 Earnings Conference Call | Earnings call |
Recent news
| Date | Headline |
|---|---|
| 2026-10-15 |
Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026
AUSTIN, Texas, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Company will report third quarter 2026 financial results on Thursday, November |
| 2026-08-28 |
Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines
AUSTIN, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that implantable paired Vagus Nerve Stimulation (VNS) has been recognized in the 2026 |
| 2026-08-11 |
Mobia Medical Reports Second Quarter 2026 Financial Results
AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial results for the quarter ended June 30, 2026. |
| 2026-08-03 |
Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors
AUSTIN, Texas, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Myriam Curet, M.D., to the Board as an independent |
| 2026-07-21 |
Mobia Medical to Report Second Quarter 2026 Financial Results on August 11, 2026
AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Company will report second quarter 2026 financial results on |
| 2026-07-15 |
Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors
AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent |
| 2026-07-14 |
Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy
Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years AUSTIN, Texas, July 14, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company |
| 2026-07-02 |
Mobia Medical Announces Vivistim® Procedure Remains Assigned to New Technology APC 1580 under CMS Proposed 2027 Hospital Outpatient Prospective Payment System Rule
AUSTIN, Texas, July 02, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Centers for Medicare and Medicaid Services (CMS) has proposed |
| 2026-05-08 |
Mobia Medical Announces Pricing of Initial Public Offering
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI) (“Mobia Medical”), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the pricing of its initial public offering of |
| 2026-02-24 |
MicroTransponder Announces Corporate Name Change to Mobia Medical
AUSTIN, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- MicroTransponder, Inc., a commercial-stage medical device company today announced that it has changed its corporate name to Mobia Medical, Inc. (“Mobia”), effective immediately. The Company develops and markets the breakthrough Vivistim ® Paired VNS™ |
| 2026-01-16 |
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
American Heart Association consortium advances development of evidence-based health tech solutions AUSTIN, Texas, Jan. 16, 2026 (GLOBE NEWSWIRE) -- MicroTransponder®, Inc., a commercial-stage medical technology company and developer of the breakthrough Vivistim® Paired VNS™ System for chronic |
| 2025-11-25 |
MicroTransponder Announces Positive Medicare Payment Change for Vivistim® Procedure
Effective January 1, 2026, the Vivistim® procedure is assigned to New Technology Ambulatory Payment Classification 1580, with an associated national average payment of approximately $45,000 AUSTIN, Texas, Nov. 25, 2025 /PRNewswire/ -- MicroTransponder®, Inc., a commercial-stage medical technology |
| 2025-11-17 |
MicroTransponder Appoints Dana G. Mead, Jr. as Chair of the Board and Adds Cynthia Lucchese as Independent Director
AUSTIN, Texas, Nov. 17, 2025 /PRNewswire/ -- MicroTransponder ®, Inc., a commercial-stage medical technology company and developer of the breakthrough Vivistim ® Paired VNS™ System for chronic stroke recovery, today announced that Dana G. Mead, Jr. has been appointed chair of its Board of |
| 2025-10-16 |
Vivistim Co-Founder Named Innovator of the Year by the Congress of Neurological Surgeons
AUSTIN, Texas, Oct. 16, 2025 /PRNewswire/ -- MicroTransponder ®, Inc., a commercial-stage medical technology company and developer of the breakthrough Vivistim ® Paired VNS ™ System for chronic stroke recovery, today announced that its co-founder and chief scientific officer, Navzer Engineer, MD, |
| 2025-06-16 |
Connecticut Passes Law to Establish $2 Million Center of Excellence to Provide Veterans with Access to FDA-Approved Vivistim Therapy for Stroke Recovery
AUSTIN, Texas, June 16, 2025 /PRNewswire/ -- MicroTransponder®, Inc., a commercial-stage medical technology company and developer of the breakthrough Vivistim® PairedVNS™ System for chronic stroke recovery, today announced that Connecticut created legislation to establish a $2 million |
| 2025-05-07 |
Chronic Stroke Survivors Demonstrate Long-Term Improvement in Motor Impairment with Vivistim Therapy
A 1-Year Follow-Up Study Published in the Peer-Reviewed Journal Stroke Validates Effectiveness of Paired Vagus Nerve Stimulation Therapy for Improved Upper Limb Function AUSTIN, Texas, May 7, 2025 /PRNewswire/ -- MicroTransponder ®, Inc., a commercial-stage medical technology company and developer |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-14 | Second Quarter 2026 Earnings Conference Call | Earnings call |
| 2026-08-11 | Second Quarter 2026 Earnings Conference Call | Earnings call |
Source: https://ir.mobia.com/